Celon Pharma (WAR:CLN) Other Financing: zł-1.0 Mil (TTM As of Mar. 2026)


WAR:CLN Celon Pharma SA WAR:CLN
48 GF Score
Price zł19.78
GF Value zł23.11
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Celon Pharma Other Financing?

Celon Pharma WAR:CLN -0.10% 48 Other Financing is zł-1.0 Mil as of Mar. 2026. GuruFocus rates WAR:CLN with a GF Score™ of 48/100 and a GF Value™ of zł23.11 (Modestly Undervalued). The stock has 3 warning signs investors should review.

Celon Pharma's Other Financing for the three months ended in Mar. 2026 was zł-0.3 Mil.

Celon Pharma's Other Financing for the trailing twelve months (TTM) ended in Mar. 2026 was zł-1.0 Mil.

Celon Pharma Other Financing Historical Data

* Premium members only.

The historical data trend for Celon Pharma's Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Celon Pharma Other Financing Chart

Celon Pharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Financing
Get a 7-Day Free Trial Premium Member Only Premium Member Only -14.30 -1.50 -2.62 -2.19 0.00

Celon Pharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.44 -0.36 -0.33 0.00 -0.31
WAR:CLN
48GF Score
Celon Pharma SA WAR:CLN
Other Financing is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Celon Pharma Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

Other Financing for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was zł-1.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Other Financing →
What does a Other Financing of zł-1.0 Mil mean?
Celon Pharma (WAR:CLN) has a Other Financing of zł-1.0 Mil as of Mar. 2026. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Celon Pharma and its competitors.
Is Celon Pharma's Other Financing too high?
Celon Pharma's current Other Financing is zł-1.0 Mil. Overall, Celon Pharma has a GF Score™ of 48/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Celon Pharma's Other Financing compare to ZTS and UTHR?
Celon Pharma's Other Financing of zł-1.0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Financing for a Drug Manufacturers company?
A good Other Financing depends on the Drug Manufacturers industry context. However, Other Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Financing mean?
A high Other Financing can signal that a stock is expensive relative to its fundamentals. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Celon Pharma and its competitors. Celon Pharma's current Other Financing is zł-1.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Celon Pharma stock overvalued right now?
Based on GuruFocus' analysis, Celon Pharma (WAR:CLN) is currently considered Modestly Undervalued. The stock's GF Value™ is zł23.11, compared to a current price of zł19.78 — trading 14.4% below its estimated fair value. The current Other Financing is zł-1.0 Mil. Celon Pharma's overall GF Score™ is 48/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Financing calculated?
Other Financing is calculated from a company's financial statements. For Celon Pharma (WAR:CLN), the current Other Financing is zł-1.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Celon Pharma (WAR:CLN) Overvalued in 2026?

Based on GuruFocus' analysis, Celon Pharma stock appears to be undervalued. The current stock price of zł19.78 is trading 14.4% below its estimated GF Value™ of zł23.11. GuruFocus considers Celon Pharma to be Modestly Undervalued.

Key valuation signals for WAR:CLN:

  • Other Financing: zł-1.0 Mil
  • GF Value™: zł23.11 vs. price of zł19.78 (14.4% below fair value)
  • GF Score™: 48/100 with 3 warning signs

No single metric tells the full story. See the WAR:CLN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Celon Pharma Business Description

Other Exchanges 8RP:Germany
Address Ogrodowa 2A, Kielpin, Lomianki, POL, 05-092
Celon Pharma SA is a Poland based company engages in the research of therapeutic solutions and development, production, distribution, and marketing of specialized generic products. It invests in the development of innovative pharmaceuticals with potential applications in the treatment of cancer, neurological diseases, diabetes and other metabolic disorders. Its products portfolio comprises pills, such as Aromek, Bosentan Celon, Donepex, Ketrel, Lazivir, and Valzek, as well as inhalation powder.
48GF Score

Get the complete analysis for WAR:CLN

Other Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

zł19.78
Price
zł23.11
GF Value